

Research & Discovery Domain John Sunderland, PhD, MBA, FSNMMI

Research and Discovery Domain Initiatives

- 1. Optimizing Readiness for Increasing Demand for Clinical RPT
- 2. Optimizing Readiness for Increasing Demand for RPT Clinical Trials
- 3. Better imaging and Quantitation and Standardization for PET and SPECT imaging
- 4. RPT Dosimetry and Industry
- 5. FNIH Dosimetry Clinical Trial Initiative
- 6. FDA Engagement
- 7. Educational Initiatives
- 8. What else should we be doing?



Optimizing Readiness for Increasing Demand for Clinical RPT: SNMMI Designated Radiopharmaceutical Therapy Centers of Excellence

Comprehensive COEs

- Dana Farber
- Duke
- Emory
- Univ. of Minnesota
- Mayo Clinic
- MD Anderson
- Memorial Sloan Kettering
- Mount Sinai
- St. Louis Univ.

- Stanford
- Ohio State
- Univ. of Minnesota
- UCLA
- UCSF
- Univ. of Colorado
- Univ. of Iowa
- Univ. of Pittsburgh



Optimizing Readiness for Increasing Demand for Clinical RPT: SNMMI Designated Radiopharmaceutical Therapy Centers of Excellence

Clinical Centers of Excellence

- ARA Theranostics Center (Austin)
- Christiana Care (Delaware)
- Excel Diagnostics and Nuclear Oncology (Houston)
- Hoag Memorial (Newport)
- Kettering Health (Kettering, Ohio)
- Northwestern Univ. (Chicago)



Optimizing Readiness for Increasing Demand for Clinical RPT: SNMMI RPT Dosimetry Certificate Program



Physician Dosimetry Certificate Program

- Didactic Curriculum
 - On-line lectures
- Practicum
 - On-Site
 - Supervised (n cases)
 - Independent (n cases)

Physicist Dosimetry Certificate Program

- Didactic Curriculum
 - On-line lectures
 - Nuclear Medicine
 - Rad Onc
- Practicum
 - On-Site
 - Supervised (n cases)
 - Independent (n cases)

Preparing the Profession for the Present and Near Future



Technologist Dosimetry Certificate Program

- Didactic Curriculum
 - On-line lectures
- Practicum
 - On-Site
 - Supervised (n cases)
 - Independent (n cases)

Optimizing Readiness for Increasing Demand for RPT Clinical Trials The SNMMI Therapy Clinical Trials Network (TCTN)

- Using the **Comprehensive RPT Centers of Excellence** as a core group of *candidate* institutions with experience and infrastructure for clinical trials, dosimetry.
- Develop standardized/harmonized methodologies for qualification for therapy trials
 - Minimum Personnel qualifications and staffing requirements
 - Quantitative SPECT and PET Scanner calibration validation procedures
 - Therapeutic administration procedures
- Creation of a searchable database with site specific
 - Equipment (scanners, dose calibrators, well counters, centrifuges, ability to store radioactive materials), radioactive materials license specifics, dosimetry software
 - Personnel (physician, physicist, pharmacists, technologists)
 - Previous therapy clinical trial experience (beta, alpha)
 - Dosimetry expertise.

Better Imaging and Quantitation and Standardization for PET and SPECT imaging

- SPECT/CT quantitative calibration program
 - CTN Initiated Being used in several industry clinical trials currently. Vendor agnostic.
 - $\,\circ\,$ Being discussed for NCTN trials
 - Being discussed for inclusion in international harmonized approach for SPECT calibration for clinical trials
 - IAC grant proposal (\$75K) in preparation for further development and inclusion in downstream clinical accreditation programs
 - NIH Grant proposal (submission February 2023 UI, UAB, NIST, SNMMI) for SPECT/CT calibration development including
 - SPECT Calibration (as above),
 - SPECT Recovery Coefficient evaluation (for use in tumor dosimetry),
 - Dose Calibrator standards creation for clinical trials (both PET and SPECT)





Better Imaging and Quantitation Secondary Standards Laboratories for Accurate Measurement of Diagnostic and Therapeutic Radionuclides

- Clear need for a rapid, accurate, radionuclide calibration service for clinical trials (diagnostic and therapeutic)
- Proposing building network of qualified academic laboratories working hand-in-hand with NIST
- Purpose:
 - Supply sponsors of clinical trials rapid and affordable secondary standard measurement of radionuclides to standardize measurements across trial sites
- Funding:
 - Seed funding from SNMMI
 - Grant funding being sought from NCI Academic Industrial Partnership grant
 - Ultimate goal financially sustainable model

Better Imaging and Quantitation for PET and SPECT The Dosimetry Challenge: Quest to Understand Magnitude and Source of Variability

7

0rgan (Gray) w b 4 0 0

Dose to

0

± 40%

Liver



- 2 Patient data sets were shared
- 321 Submission from 51 sites around the globe



Dosimetry Challenge Organ Doses Patient A

± 33%

R Kidney

Dosimetry Challenge Lesion Doses Patient B

± 31%

L Kidney

± 40%

Spleen

SPECT 4TP

Planar4TP

SPECT 1 TP +

Planar x 3 TP

Community Awareness of Dosimetry and Dosimetry Tools:

- Annual Meeting in Vancouver: Industry Hands-On Dosimetry Open House – Targeting Physicists
- SNMMI Fall Therapeutics Conference, November 17-19, 2022 in DC:
 - Industry Hands-On Dosimetry Open House Targeting *Physicians*
 - Utility of dosimetry programmed into each session (Thyroid, prostate, neuroendocrine)



Enhanced Efficacy of RPT Through Dosimetry: The FNIH Initiative : New

- The FNIH Model
 - High impact trials in the pre-competitive space
 - Funded primarily by a shared-cost model by a consortium of industry partners that stand to benefit from the clinical trial
 - Contributing funders can and should contribute to trial design.
- NCI has proposed a Prostate Ca dosimetry guided Therapeutic trial with Lu-177 PSMA (Pluvicto)
- FNIH scheduled presentation two weeks ago (NCI presented)
 - Follow-up meeting imminent
- In a parallel, serendipitous effort, a physician-based Dosimetry Task Force Subgroup has been developing a Dosimetry-Guided Prostate Cancer RPT trial.
 - This is being handed off to a physicist-based Dosimetry Task Force Subgroup
 - Potential Primary, Secondary, and Tertiary Endpoints being discussed
 - Tumor Dosimetry Guided
 - Investigating Higher Administered Doses (>200 mCi) guided by dosimetry
 - Investigating not limiting number of cycles (using dosimetry and AEs as stopping rules)
 - Investigating Tumor Dosimetry Guided Cohorts
 - Investigating Global Average Tumor Dose as Guidance for Predicting Response

SNMMI/FDA Engagement

Therapeutic space

- Subgroup drafting a Phase 1-2 manuscript defining what, optimally, should be required and collected for dosimetry in early phase trials
 - Specific recommendations targeting what FDA should and should not require for Beta and alpha-emitting radiopharmaceuticals
- A mitigation strategy for the approved standardized (e.g. 200 mCi) doses
 - how do we backtrack to using personalized doses where we can give higher/lower doses as dosimetry dictates?

Diagnostic space

- How to deal more effectively and efficiently in the non-proprietary space
 - FDA cites "real world evidence" from literature can be used, but this is too vague for planning.

Educational Initiatives for New Radiopharmaceuticals

- Creation of Web-based voice-over PowerPoint style didactic training for new radiopharmaceuticals
 - Basic background science
 - Case-based examples
- In-Person Case-Based training for new radiopharmaceuticals
 - Individual iPads issued to each participant, pre-loaded with sample cases (DICOM)
 - Expert facilitator leading case presentation and discussion interactive
- **NEW!** Cloud-based DICOM image server with entire case studies loaded
 - Clinical metadata provided
 - Fully functional image viewing and analysis software available
 - Walks the learner through key findings
 - Entirely remote
 - Amyloid imaging is the first use-case

What Else Should We Be Doing?

Questions?

